For LINC00511, it can combine with EZH2 and LSD1 in vivo, downregulate the expression of LATS2 and KLF2, and promote the progression of NSCLC (Zhu F. Y. et al., 2019). This evidence concerns the gene KDM1A and non-small cell lung carcinoma.